ARGATROBAN 100 MG
ARGATROBAN : 100 MG · DIN 02243835 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED POST MARKET
What is ARGATROBAN?
ARGATROBAN 100 MG contains ARGATROBAN : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02243835, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ARGATROBAN used for?
Anticoagulant therapy in patients with heparin-induced thrombocytopenia syndrome who require anticoagulation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02243835 |
|---|---|
| Brand name | ARGATROBAN |
| Generic / active ingredient | ARGATROBAN : 100 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 100 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B01AE03 ARGATROBAN |
| AHFS class | 20:12.04.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jul-2025 |
| Original market date | 2002-06-13 00:00:00 |
How is it administered?
Initial dose: 2 mcg/kg/min continuous infusion. Adjust to maintain aPTT 1.5–3.0 times baseline (max 100s). Reduce dose in hepatic impairment. Monitor aPTT 2 hours after initiation.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Diluted solutions: 24 hours at 15-25°C (ambient light) or 48 hours at 2-8°C (dark).
How is it supplied?
100 mg/mL: 2.5 mL single-use vials (250 mg). 1 mg/mL: 50 mL single-use vials (50 mg).
Contraindications
Active major bleeding; hypersensitivity to the drug or any ingredient; hereditary fructose intolerance.
Warnings and precautions
Hemorrhage risk; use with extreme caution in states with increased bleeding danger (e.g., severe hypertension, major surgery). Monitor all patients carefully.
What can be used instead?
Other Canadian products sharing ATC code B01AE03 ARGATROBAN. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARGATROBAN | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02548968 |
Who else supplies ARGATROBAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ARGATROBAN appears in 4 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.